Related Experiment Videos
Highlights in the development of new antiviral agents
1Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, B-3000, Belgium. erik.declercq@rega.kuleuven.ac.be
Mini Reviews in Medicinal Chemistry
|October 9, 2002
Summary
This study reviews novel antiviral compounds and strategies targeting major viral infections like HIV, influenza, and herpesviruses. It highlights diverse inhibitors, including fusion, reverse transcriptase, and protease inhibitors, for improved viral disease treatment.
Area of Science:
- Virology
- Medicinal Chemistry
- Drug Discovery
Background:
- The emergence of diverse viral infections necessitates the development of novel therapeutic agents.
- Existing antiviral treatments face challenges including resistance and limited efficacy against certain viruses.
- A broad spectrum of viral pathogens requires a multifaceted approach to antiviral drug development.
Purpose of the Study:
- To comprehensively review emerging antiviral compounds and therapeutic strategies.
- To address the treatment of major human viral infections, including HIV, influenza, and herpesviruses.
- To categorize and discuss various classes of antiviral inhibitors based on their mechanisms of action.
Main Methods:
- Literature review of recent advancements in antiviral drug discovery.
- Categorization of antiviral agents by their molecular targets and mechanisms (e.g., adsorption, fusion, replication, transcription, assembly).
- Compilation of specific compound examples and their associated viral targets.
Main Results:
- Identified numerous novel compounds targeting HIV, including adsorption inhibitors, co-receptor antagonists, fusion inhibitors, and various classes of reverse transcriptase inhibitors (NRTIs, NNRTIs).
- Detailed inhibitors for other viral families: RSV/paramyxovirus (fusion inhibitors), picornavirus (uncoating inhibitors), herpesviruses (DNA polymerase inhibitors), influenza (neuraminidase inhibitors), and hepatitis viruses (RNA replicase, N-glycosylation inhibitors).
- Highlighted broader-acting antivirals like IMP dehydrogenase and S-adenosylhomocysteine hydrolase inhibitors for diverse viral infections, including hemorrhagic fevers.
Conclusions:
- A wide array of new antiviral compounds and strategies are under investigation for numerous viral infections.
- Targeting diverse stages of the viral life cycle offers promising avenues for effective antiviral therapies.
- Continued research into novel inhibitors is crucial for combating the global burden of viral diseases.